Buscar
Uniqure NV
QUREAñadir a la lista de seguimiento
45.170USD
-0.890-1.93%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
2.85BCap. mercado
PérdidaP/E TTM
Más Datos de Uniqure NV Compañía
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Información de Uniqure NV
Símbolo de cotizaciónQURE
Nombre de la empresaUniqure NV
Fecha de salida a bolsaFeb 05, 2014
Director ejecutivoKapusta (Matthew)
Número de empleados209
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónPaasheuvelweg 25a
CiudadAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1105 BP
Teléfono31202406000
Sitio Webhttps://www.uniqure.com/
Símbolo de cotizaciónQURE
Fecha de salida a bolsaFeb 05, 2014
Director ejecutivoKapusta (Matthew)
Ejecutivos de Uniqure NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
27.52K
+20.19%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
25.93K
+21.43%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
63.73K
-31.38%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
35.28K
+15.75%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Uniqure NV?
Los cinco principales accionistas de Uniqure NV son: Mr. Christian Klemt, CPA
¿Cuántas instituciones poseen acciones de Uniqure NV (QURE)?
A fecha de 2026Q1, 481 instituciones poseen acciones de Uniqure NV, con un valor de mercado combinado de aproximadamente 65.80M, lo que representa el 104.34% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1601871.00.